Allurion Technologies Inc (NYSE:ALUR) reports strong growth in recurring revenue from its AI-native platform, Allurion Virtual Care Suite (VCS), with a new commercial strategy. FDA approval for the Allurion balloon is pending, alongside operational restructuring for cost efficiency.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing